DGAP-Adhoc: Alphaform AG: Alphaform Supervisory Board

Alphaform AG / Key word(s): Change of Personnel 15.09.2014 21:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc disclosure Alphaform AG Alphaform Supervisory Board appoints Thomas Kresser as Chief Financial Officer Feldkirchen, 15 September 2014 - The Supervisory Board of Alphaform AG has today decided to appoint Mr Thomas Kresser (55) to the company's Management Board, effective 1 October 2014. He will manage the company as Chief Financial Officer alongside CEO Dr Hanns-Dieter Aberle. Kresser has more than 15 years of management experience as General Manager and CFO. He is at home both in the consumer goods and industrial customer businesses and has extensive experience in turnaround and restructuring projects and growth strategies. Most recently, he was Chief Financial Officer at Alstom Deutschland AG. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About Alphaform Alphaform AG, based in Feldkirchen near Munich was founded in 1996. The company belongs to the European market leaders in the production of complex components means additive manufacturing, which are often grouped together under the term '3D printing'. An important mainstay of the segment 3D Printing an Additive Manufacturing ist the production of series close prototypes, particularly for the automotive and capital goods industries. The Medical Devision of Alphaform has al leading position throughout Europe in manufacturing and processing orthopaedic implants and instruments. The shares of alphaform are listed in the Prime Standard Segment of the Frankfurt Stock Exchange (FWB) under the abbreviation ATF. The core competence of Alphaform lies in its extensive application know how for processes and materials for additive production of complex prototypes, tools, individual components and small series made of plastic and metal. The company's activity is focused on the orthopaedic and medical technology, automotive, aviation and aerospace industries. The subsidiaries of Alphaform are located in Germany, Finland, Sweden and the UK. Contact: Dr. Hanns-Dieter Aberle, CEO ALPHAFORM AG Kapellenstraße 10 85622 Feldkirchen Tel.: +49 89 905002 35 Fax: +49 89 905002 1035 e-mail: hdaberle@alphaform.de Internet: www.alphaform.de Disclaimer This press release/ad-hoc disclosure is not an offer document and does not constitute an offer of shares of Alphaform AG ('Company') nor an invitation to an offer to buy or subscribe for shares or securities of the Company but is provided for information only. This press release/ad-hoc disclosure may contain forward-looking statements that are subject to risks and uncertainties, including those pertaining to the anticipated benefits to be realized from the proposals described herein. Forward-looking statements may include, in particular, statements about future events, future financial performance, plans, strategies, expectations, prospects, competitive environment, regulation and supply and demand. The Company has based these forward-looking statements on its views and assumptions with respect to future events and financial performance. Actual financial performance could differ materially from that projected in the forward-looking statements due to the inherent uncertainty of estimates, forecasts and projections, and financial performance may be better or worse than anticipated. Given these uncertainties, persons should not put undue reliance on any forward-looking statements. The information contained in this presentation is subject to change without notice and the Company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable laws and regulations. Important notice to persons in the United States of America All information in this press release/ad-hoc disclosure is being made available in the United States of America only to persons believed by the Company to be capable of understanding and evaluating the risks of a transaction. No shares or other securities of the Company have been registered or otherwise qualify for a public sale or resale under federal or state laws in the United States of America. Each recipient of information doing business in or organized under any federal or state laws in the United States of America or in areas subject to its jurisdiction represents that it is an 'accredited investor' as defined by Rule 501 or Regulation D under the Securities Act of 1993 ('the Act') and acknowledges that none of the shares in the Company will be registered under the Act and cannot be resold in the absence of such registration or the availability of an exemption there from. The shares in the Company have not been approved or disapproved by the United States Securities and Exchange Commission, any state securities commission or other regulatory authority, nor have any of these authorities passed judgment upon or endorsed the merits of an investment in the shares of the Company or the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offence. Important notice to persons in the United Kingdom All information in this press release/ad-hoc disclosure is being made available to the recipients on the basis that they are persons covered by Article 11(3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996. By accepting this document the recipient warrants and represents that he or it is such a person. 15.09.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Alphaform AG Kapellenstraße 10 85622 Feldkirchen Germany Phone: +49 (0)89 905002 - 0 Fax: +49 (0)89 905002 - 90 E-mail: ir@alphaform.de Internet: www.alphaform.de ISIN: DE0005487953 WKN: 548795 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------